Redeye provides a brief comment on Freemelt's order from a global orthopedic implant OEM, marking a ...
Förvärvet av TrustPlay, med tillhörande teknikportfölj, positionerar Tangiamo i framkant av den växa...
Redeye comments on Freemelt ahead of its Q3 results, due on 5 November.
Redeye offers a preview of Doro's Q3 results set to be released on October 25.
Minor estimate changes Gross margin improvements set to continue Trading at NTM EV/EBITA of ~10x Wh...
Minor near-term estimate cuts following the cyberattack Outlook for order intake unchanged NTM EV/EB...
Q3'24 results due 25 October '24e-'26e adj. EBIT revised down 0.
Solid Q3e with 7% organic growth and 22% EBITDA growth US market could be sluggish again, but focus ...
Efterfrågan har överlag hittills varit stabil, men med en svagare efterfrågan inom de breda industri...
Redeye expects a stable Q3 report from Addnode with limited growth yet solid margins.
Leader in children's smartwatches, entering new verticals ~800k subscriptions and 52% EBITA CAGR by ...
Redeye comments on Truecaller ahead of its Q3 results, which are due on 7 November.
Q3e: -1% organic sales growth y-o-y, 7% adj. EBITA margin We decrease '25e-'26e sales by 2% Trading ...
VIMAB Group är en industrikoncern verksamt inom miljö, elektrifiering och near-shoring.
Redeye presents its preview of Sedana Medical’s Q3 2024 report, due October 24.
Redeye gives its preview on OssDsign’s Q3 2024 report, due on November 5.
Redeye offers a preview of SSH's Q3 results set to be released on October 24.
• Q3: EBITDA of ~NOK 10m • New targets achievable, but lower range more likely • Recovery postponed ...
Kinda Brave Entertainment Group AB (”Kinda Brave” eller ”Koncernen”) meddelade den 10 oktober 2024 a...
Duell is advancing its turnaround amidst a challenging market, with overall risk reduced due to bala...
